IQWiG’s Nods To Boehringer’s Giotrif and Novartis’ Ultibro Raise Submission Strategy Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s IQWiG has cleared Boehringer’s Giotrif for lung cancer and Novartis’ Ultibro Breezhaler for COPD, raising questions as to what HTA submission strategy drugs firms should adopt.
You may also be interested in...
Breo Coverage Gaining Ground, GSK’s Witty Assures Investors
GlaxoSmithKline’s COPD drug Breo Ellipta is facing reimbursement challenges, particularly in terms of Medicare Part D coverage. But CEO Andrew Witty told investors during a year-end sales and earnings call Feb. 5 that coverage is increasing and will continue to grow through 2014.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.